WHO backs rollout of new HIV prevention drug in 9 countries
The World Health Organization (WHO) says it has supported nine countries to begin rolling out lenacapavir, a long-acting HIV prevention medicine, targeting people at high risk of infection across several African nations.
The disclosure was made on Thursday by Tedros Adhanom Ghebreyesus, Director-General of the WHO, during an online media briefing addressing global health priorities, including HIV prevention, obesity treatment advances and progress in cervical cancer elimination.
Tedros said a new medicine approved in 2025 for HIV prevention, Lenacapavir, represented the most significant development in combating HIV since the first antiretroviral treatments were approved nearly 40 years ago.
He said that HIV remained one of the defining public health challenges of the past half-century, but it had also become one of the world’s most notable successes in disease control efforts.
According to him, HIV, once considered a death sentence, can now be controlled with safe and effective medication, allowing millions of people living with the virus to live longer, healthier lives worldwide.
Tedros said that as treatment improved and access expanded, annual AIDS-related deaths globally had dropped dramatically, declining by about 70 per cent over the past 20 years.
He added that medicines originally designed to treat HIV infection were increasingly used as preventive tools, protecting people at substantial risk of contracting the virus before exposure occurred.
The WHO chief reiterated that the approval of Lenacapavir for HIV prevention in 2025 marked a historic milestone in global efforts to curb transmission and accelerate progress toward ending the epidemic.
He explained that lenacapavir was not a vaccine but functioned as a long-acting antiretroviral drug administered once every six months to people who were HIV-negative but vulnerable to infection.
According to him, clinical trials have shown the medicine can prevent almost all cases of HIV among individuals at risk, making it one of the most promising prevention tools available.
Tedros said WHO issued official guidelines on the use of Lenacapavir in July 2025 and later granted prequalification in October, enabling global health donors to procure and distribute the medicine.
He said that it was the first time the WHO developed treatment guidelines and product prequalification simultaneously rather than sequentially, accelerating equitable access to a major public health innovation.
Tedros said South Africa became the first African country to approve lenacapavir in Oct. 2025, and only the third country globally to authorise the medicine for HIV prevention.
He added that Cyril Ramaphosa, President of South Africa, announced during his 2025 State of the Nation address that the country planned a large-scale rollout of the prevention drug.
“South Africa also announced plans on Thursday to manufacture Lenacapavir locally, a move expected to strengthen supply and expand access to the medicine across the region.”
Tedros warned that demand for the drug was currently exceeding supply, as orders placed by countries through donors had fallen short of the growing need.
He said the WHO was working with national governments, international donors and pharmaceutical manufacturers to scale up production and ensured sufficient supplies reached countries introducing the medicine.
Turning to obesity, Tedros described it as one of the most pressing health challenges globally but said new treatment tools, including GLP‑1 therapies, are expanding options for care.
He said the WHO issued its first guideline in Dec. 2025 recommending the use of GLP‑1 therapies for the treatment of obesity in adults as part of comprehensive care strategies.
Tedros emphasised that medication alone could not reverse obesity, but when combined with healthy diets, regular physical activity and professional medical support; it could significantly improve treatment outcomes.
He said the new guidance had generated strong interest from countries seeking to integrate GLP‑1 therapies into national obesity management programmes and health systems.
According to him, WHO researchers also published a study in The Lancet Global Health outlining efforts to help twelve countries strengthen health systems to deliver improved obesity care.
Through the WHO Acceleration Plan to Stop Obesity, Tedros said the organisation was supporting 34 countries representing about 1.3 billion people to reduce obesity prevalence by five per cent by 2030.
He said governments were adopting measures including taxes on sugary drinks and integrating obesity treatment services into primary healthcare systems to improve prevention and management.
Tedros urged countries worldwide to scale up all available tools to prevent and treat obesity across all age groups, stressing that coordinated action was essential to reversing rising global trends.
He also highlighted the HPV vaccine as another powerful public health tool helping countries move closer to eliminating cervical cancer through vaccination, screening and early treatment.
Tedros noted that Wednesday marked HPV Awareness Day, celebrated under the theme “One Less Worry,” raising awareness about viruses responsible for several cancers, including cervical cancer.
He recalled launching a global call in 2018 to eliminate cervical cancer, followed in 2020 by a global strategy targeting 90 per cent vaccination and 90 per cent screening coverage.
“The strategy also aims to ensure 90 per cent of women diagnosed with cervical cancer or precancerous lesions receive treatment by 2030, significantly reducing global mortality from the disease.”
Tedros said nearly 60 countries had introduced HPV vaccination programmes since the initiative began, while 162 countries now included the vaccine in national immunisation schedules.
He highlighted progress in India and South Africa, describing both countries as making major strides toward eliminating cervical cancer through expanded vaccination campaigns and national programmes.
“In February, India launched the largest free HPV vaccination campaign in history, targeting nearly 12 million fourteen-year-old girls every year to protect them against cervical cancer.
“More than 127,000 women in India are diagnosed with cervical cancer annually, while about 80,000 die from the disease each year, according to global health estimates.”
Tedros commended Narendra Modi and the Government of India for demonstrating leadership in tackling cervical cancer through expanded vaccination and national health interventions.(NAN)